Alderley Park Ventures (APV), the investment fund created in late 2014 and managed by BioCity, has made an initial investment into NeuDrive to help develop technology which will be applied in the Biosensor field.

Dr Claire Brown at APV said:

“We chose to invest in NeuDrive because we were impressed by the breadth of application of their proprietary organic printable electronics platform (FlexOS™). While NeuDrive continues to exploit the application of their exciting technology in the backplane displays arena, they had also identified the potential for their technology in Life science and Healthcare in the development of novel sensors.

“This extremely dynamic sector – where remote monitoring and wearable devices is a hot topic – is one that, by working closely with them on the BioCity Accelerator DEVELOP programmes we hope we can help unlock the full potential of this exciting technology.”

Malcolm Stewart, CEO of NeuDrive, added: “We were keen to have the involvement of APV as we are interested in developing the applications of our technology in healthcare and the strong links of APV into this sector provide an ideal opportunity to strengthen our network in this area.   The APV funding has been earmarked to support our proof of concept work in biosensors alongside our ongoing commercialisation of the FlexOS™ organic semiconductor inks platform in flexible display applications.”